The BPC-157/TB-500 (5/5) blend from Adaptog Peptides combines two of the most widely investigated peptides in tissue-repair and cytoprotection research. Each vial pairs 5mg of BPC-157 with 5mg of TB-500, giving researchers a single reagent for studies that examine the combined or comparative effects of both compounds. Adaptog supplies this blend at consistent purity for reproducible experimental work.
BPC-157 and TB-500 are studied across overlapping research areas including angiogenesis, fibroblast activity, and connective-tissue modelling. Combining them in a single vial allows investigators to streamline protocols when their experimental design calls for parallel exposure. Adaptog Peptides supplies the BPC-157/TB-500 (5/5) blend so laboratories can run efficient, well-controlled studies without managing two separate reconstitutions.
Researchers often buy the BPC-157/TB-500 blend from Adaptog Peptides for tasks such as:
Examining additive or comparative effects on cellular migration and repair pathways
Investigating angiogenic markers in controlled in-vitro models
Studying interactions between cytoprotective and actin-binding mechanisms
Streamlining workflows that require both peptides at fixed ratios
Because both peptides have well-documented research profiles, this blend is a practical reagent for laboratories already familiar with each compound. Adaptog Peptides delivers BPC-157/TB-500 (5/5) as a high-purity laboratory blend intended exclusively for qualified research environments. It serves no clinical, diagnostic, or therapeutic purpose.
For research use only. Not for human consumption.
BPC-157 and TB-500 are studied across overlapping research areas including angiogenesis, fibroblast activity, and connective-tissue modelling. Combining them in a single vial allows investigators to streamline protocols when their experimental design calls for parallel exposure. Adaptog Peptides supplies the BPC-157/TB-500 (5/5) blend so laboratories can run efficient, well-controlled studies without managing two separate reconstitutions.
Researchers often buy the BPC-157/TB-500 blend from Adaptog Peptides for tasks such as:
Examining additive or comparative effects on cellular migration and repair pathways
Investigating angiogenic markers in controlled in-vitro models
Studying interactions between cytoprotective and actin-binding mechanisms
Streamlining workflows that require both peptides at fixed ratios
Because both peptides have well-documented research profiles, this blend is a practical reagent for laboratories already familiar with each compound. Adaptog Peptides delivers BPC-157/TB-500 (5/5) as a high-purity laboratory blend intended exclusively for qualified research environments. It serves no clinical, diagnostic, or therapeutic purpose.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
